W.T.M. Vree Egberts

1.3k total citations
7 papers, 921 citations indexed

About

W.T.M. Vree Egberts is a scholar working on Epidemiology, Immunology and Molecular Biology. According to data from OpenAlex, W.T.M. Vree Egberts has authored 7 papers receiving a total of 921 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 4 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in W.T.M. Vree Egberts's work include Inflammatory Myopathies and Dermatomyositis (7 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Muscle Physiology and Disorders (2 papers). W.T.M. Vree Egberts is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (7 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Muscle Physiology and Disorders (2 papers). W.T.M. Vree Egberts collaborates with scholars based in Netherlands, Sweden and Czechia. W.T.M. Vree Egberts's co-authors include Baziel G.M. van Engelen, G.J.D. Hengstman, Jiří Vencovský, Ingrid E. Lundberg, Haralampos Μ. Moutsopoulos, Walther J. van Venrooij, H. P. Seelig, Andrea Doria, P.J.H. Jongen and Marta Mosca and has published in prestigious journals such as Annals of the Rheumatic Diseases, Clinical & Experimental Immunology and Journal of Neurology.

In The Last Decade

W.T.M. Vree Egberts

7 papers receiving 899 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
W.T.M. Vree Egberts 813 423 249 244 179 7 921
Edward P. Trieu 737 0.9× 522 1.2× 263 1.1× 262 1.1× 148 0.8× 13 1.0k
Sevim Barbasso Helmers 702 0.9× 376 0.9× 287 1.2× 175 0.7× 144 0.8× 17 884
Akinori Uruha 853 1.0× 381 0.9× 192 0.8× 330 1.4× 146 0.8× 51 1.1k
Sarah Tansley 1.4k 1.8× 887 2.1× 406 1.6× 332 1.4× 217 1.2× 50 1.6k
Grace Hong 615 0.8× 208 0.5× 158 0.6× 156 0.6× 159 0.9× 5 672
Ronan J. Walsh 422 0.5× 271 0.6× 181 0.7× 287 1.2× 78 0.4× 13 721
M. Hietarinta 321 0.4× 199 0.5× 108 0.4× 94 0.4× 109 0.6× 13 518
Christopher Marguerie 355 0.4× 199 0.5× 184 0.7× 77 0.3× 78 0.4× 13 578
Damien Amelin 372 0.5× 149 0.4× 84 0.3× 134 0.5× 64 0.4× 9 433
Eva Lindroos 382 0.5× 123 0.3× 170 0.7× 180 0.7× 51 0.3× 12 525

Countries citing papers authored by W.T.M. Vree Egberts

Since Specialization
Citations

This map shows the geographic impact of W.T.M. Vree Egberts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.T.M. Vree Egberts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.T.M. Vree Egberts more than expected).

Fields of papers citing papers by W.T.M. Vree Egberts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.T.M. Vree Egberts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.T.M. Vree Egberts. The network helps show where W.T.M. Vree Egberts may publish in the future.

Co-authorship network of co-authors of W.T.M. Vree Egberts

This figure shows the co-authorship network connecting the top 25 collaborators of W.T.M. Vree Egberts. A scholar is included among the top collaborators of W.T.M. Vree Egberts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.T.M. Vree Egberts. W.T.M. Vree Egberts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Hengstman, G.J.D., H. J. ter Laak, W.T.M. Vree Egberts, et al.. (2006). Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Annals of the Rheumatic Diseases. 65(12). 1635–1638. 239 indexed citations
2.
Hengstman, G.J.D., W.T.M. Vree Egberts, H. P. Seelig, et al.. (2006). Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Annals of the Rheumatic Diseases. 65(2). 242–245. 107 indexed citations
3.
Hengstman, G.J.D., W.T.M. Vree Egberts, E.L. van der Kooi, et al.. (2005). High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. Journal of Neurology. 252(5). 534–537. 25 indexed citations
4.
Hengstman, G.J.D., R M Brouwer, W.T.M. Vree Egberts, et al.. (2002). Clinical and serological characteristics of 125 Dutch myositis patients. Journal of Neurology. 249(1). 69–75. 74 indexed citations
5.
Brouwer, R M, G.J.D. Hengstman, W.T.M. Vree Egberts, et al.. (2001). Autoantibody profiles in the sera of European patients with myositis. Annals of the Rheumatic Diseases. 60(2). 116–123. 288 indexed citations
6.
Hengstman, G.J.D., Baziel G.M. van Engelen, W.T.M. Vree Egberts, & Walther J. van Venrooij. (2001). Myositis-specific autoantibodies: overview and recent developments. Current Opinion in Rheumatology. 13(6). 476–482. 39 indexed citations
7.
Rutjes, Saskia A., et al.. (1997). Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clinical & Experimental Immunology. 109(1). 32–40. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026